Erectile function rehabilitation in the radical prostatectomy patient

Journal of Sexual Medicine

Volumn 7, Issue 4 PART 2, 2010, Pages 1687-1698

  Mulhall, John P ^a   Bella, Anthony J ^b   Briganti, Alberto ^c   McCullough, Andrew ^d   Brock, Gerald ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Collagen; Intracavernosal Injections; Oxygenation; PDE5 Inhibitor; Prostate Cancer; Prostatectomy; Radiation; Rehabilitation; Smooth Muscle

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CANCER PATIENT; CLINICAL TRIAL; DATA ANALYSIS; DELPHI STUDY; ERECTILE DYSFUNCTION; HUMAN; MEDICAL EXPERT; MEDICAL SOCIETY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT DECISION MAKING; PENIS ERECTION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REHABILITATION CARE;

EID: 77955252679     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01804.x     Document Type: Article

References (45)

1. Briganti A, Salonia A, Gallina A. Management of erectile dysfunction after radical prostatectomy in 2007. World J Urol 2007, 25:143-8.
2. Burnett AL. Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology 2003, 61:491-87.
3. Chuang MS, O'Connor RC, Laven BA, Orvieto MA, Brendler CB. Early release of the neurovascular bundles and optical loupe magnification lead to improved and earlier return of potency following radical retropubic prostatectomy. J Urol 2005, 173:537-9.
4. Carrier S, Zvara P, Nunes L, Kour NW, Rehman J, Lue TF. Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol 1995, 153:1722-7.
5. Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol 2005, 173:1673-6.
6. Leungwattanakij S, Bivalacqua TJ, Usta MF. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003, 24:239-45.
7. Montorsi F, Brock G, Lee J. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008, 54:924-31.
8. Mulhall JP. Exploring the potential role of neuromodulatory drugs in the radical prostatectomy patient. J Androl 2009
9. Padma-Nathan H, McCullough AR, Levine LA. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008, 20:479-86.
10. Parsons JK, Marschke P, Maples P, Walsh PC. Effect of methylprednisolone on return of sexual function after nerve-sparing radical retropubic prostatectomy. Urology 2004, 64:987-90.
11. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: Improvement with nightly low-dose sildenafil. BJU Int 2008, 101:1279-83.
12. Zippe CD, Pahlajani G. Penile rehabilitation following radical prostatectomy: Role of early intervention and chronic therapy. Urol Clin North Am 2007, 34:601-18.
13. Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: Challenges and misconceptions. J Urol 2009, 181:462-71.
14. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008, 18:613-20.
15. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006, 68:429-35.
16. Ferrini MG, Kovanecz I, Sanchez S, Umeh C, Rajfer J, Gonzalez-Cadavid NF. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med 2009, 6:415-28.
17. Kovanecz I, Rambhatla A, Ferrini M. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2008, 20:202-12.
18. Kovanecz I, Rambhatla A, Ferrini MG. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008, 101:203-10.
19. Mulhall JP, Muller A, Donohue JF. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med 2008
20. Vignozzi L, Filippi S, Morelli A. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006, 3:419-31.
21. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des 2005, 11:4041-6.
22. Foresta C, Di Mambro A, Caretta N, De Toni L, Zuccarello D, Ferlin A. Effect of vardenafil on endothelial progenitor cells in hypogonadotropic hypogonadal patients: Role of testosterone treatment. Clin Endocrinol (Oxf) 2009, 71:412-6.
23. Foresta C, Ferlin A, De Toni L. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006, 18:484-8.
24. Foresta C, Lana A, Cabrelle A. PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 2005, 17:377-80.
25. Behr-Roussel D, Gorny D, Mevel K. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: Lack of tachyphylaxis. Eur Urol 2005, 47:87-91.
26. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: Role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005, 68:226-32.
27. Foresta C, De Toni L, Di Mambro A, Garolla A, Ferlin A, Zuccarello D. The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. J Sex Med 2009, 6:369-72.
28. Lysiak JJ, Yang SK, Klausner AP, Son H, Tuttle JB, Steers WD. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J Urol 2008, 179:779-85.
29. Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, Kukreja RC. Vardenafil: A novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 2006, 40:405-11.
30. Salloum FN, Takenoshita Y, Ockaili RA. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007, 42:453-8.
31. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944-55.
32. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005, 111:1601-10.
33. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: Practice patterns among the international society for sexual medicine practitioners. J Sex Med 2009, 6:2032-8.
34. Montorsi F, Guazzoni G, Strambi LF. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997, 158:1408-10.
35. Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005, 2:532-40. discussion 40-2
36. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004, 171:771-4.
37. Ghofrani HA, Voswinckel R, Reichenberger F. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol 2004, 44:1488-96.
38. Aizawa K, Hanaoka T, Kasai H. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006, 29:123-8.
39. Giacomini M, Borotto E, Bosotti L. Vardenafil and weaning from inhaled nitric oxide: Effect on pulmonary hypertension in ARDS. Anaesth Intensive Care 2007, 35:91-3.
40. Bosshardt RJ, Farwerk R, Sikora R, Sohn M, Jakse G. Objective measurement of the effectiveness, therapeutic succes and dynamic mechanisms of the vacuum device. BJU 1995, 75:786-91.
41. Raina R, Agarwal A, Ausmundson S. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006, 18:77-81.
42. Dalkin BL, Christopher BA. Preservation of penile length after radical prostatectomy: Early intervention with a vacuum erection device. Int J Impot Res 2007, 19:501-4.
43. Kohler TS, Pedro R, Hendlin K. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 2007, 100:858-62.
44. Costabile RA, Spevak M, Fishman IJ. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998, 160:1325-8.
45. Raina R, Agarwal A, Zaramo CE, Ausmundson S, Mansour D, Zippe CD. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2005, 17:86-90.